• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ZimVie Inc.

    11/14/24 4:11:11 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email
    SC 13G 1 o114246sc13g.htm

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.) *

     

    ZIMVIE Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    98888T107

    (CUSIP Number)

     

    Kamran Moghtaderi, Eversept Partners, L.P., 444 Madison Avenue, 22nd Floor, New York, NY 10022, 212-271-4211

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

       
     

     

    CUSIP No. 98888T107   13G   Page 2 of 9 Pages
             

             
    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Eversept Partners, L.P.

    47-5115829

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

      5.   SOLE VOTING POWER
     
    1,928,493
      6.   SHARED VOTING POWER
     
    142,287*
      7.   SOLE DISPOSITIVE POWER
     
    1,928,493
      8.   SHARED DISPOSITIVE POWER
     
    142,287*

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,070,780
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.5%**
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       

     

    *See Item 4 of the Schedule 13G

     

       
     

     

    CUSIP No. 98888T107   13G   Page 3 of 9 Pages
             

             
    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Eversept 1 LLC

    81-4423039

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

      5.   SOLE VOTING POWER
     
    1,928,493
      6.   SHARED VOTING POWER
     
    142,287*
      7.   SOLE DISPOSITIVE POWER
     
    1,928,493
      8.   SHARED DISPOSITIVE POWER
     
    142,287*

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,070,780
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.5%**
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    HC
       

     

    *See Item 4 of the Schedule 13G

     

       
     

     

    CUSIP No. 98888T107   13G   Page 4 of 9 Pages
             

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Kamran Moghtaderi
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

      5.   SOLE VOTING POWER
     
    1,928,493
      6.   SHARED VOTING POWER
     
    142,287*
      7.   SOLE DISPOSITIVE POWER
     
    1,928,493
      8.   SHARED DISPOSITIVE POWER
     
    142,287*

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,070,780
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.5%**
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN, HC
       

     

    *See Item 4 of the Schedule 13G

     

       
     

     

    CUSIP No. 98888T107   13G   Page 5 of 9 Pages
             

     

    Item 1.

     

      (a) Name of Issuer
    ZIMVIE Inc.
         
      (b)

    Address of Issuer’s Principal Executive Offices
    4555 Riverside Drive

    Palm Beach Gardens, FL 33410

         

     

    Item 2.

     

      (a)

    Name of Person Filing


    This statement is jointly filed by and on behalf of Eversept Partners, L.P., a Delaware limited partnership (the “Investment Manager”), Eversept 1 LLC, a Delaware limited liability company (the “IM GP”) and Kamran Moghtaderi (collectively referred herein as “Reporting Persons”). The Investment Manager is the investment manager of advisory clients, and may be deemed to indirectly beneficially own securities owned by its advisory clients. The IM GP is the general partner of the Investment Manager and may be deemed to indirectly beneficially own securities owned by the Investment Manager. Mr. Moghtaderi is the sole manager of, and may be deemed to beneficially own securities beneficially owned by, the IM GP. Eversept’s advisory clients are the record and direct beneficial owners of the securities covered by this statement.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.

         
      (b) Address of the Principal Office or, if none, residence
    The address of the principal business office of each of the Reporting Persons is c/o Eversept Partners, L.P., 444 Madison Avenue, 22nd Floor, New York, NY 10022.
         
      (c) Citizenship
    See Item 4 on the cover page hereto.
         
      (d) Title of Class of Securities
    Common Stock, par value $0.01 per share
         
      (e) CUSIP Number
    98888T107

     

       
     

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

     

    Item 4.  Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:  2,070,780
             
      (b)   Percent of class: 7.5%** 
             
      (c)   Number of shares as to which the person has:  
             
          (i) Sole power to vote or to direct the vote 1,928,493
             
          (ii) Shared power to vote or to direct the vote 142,287*
             
          (iii) Sole power to dispose or to direct the disposition of 1,928,493
             
          (iv)

    Shared power to dispose or to direct the disposition of 142,287*

     

    * Note: As of the close of business on September 30, 2024, Eversept and its controlling persons beneficially owned 2,070,780 Shares, including 142,287 Shares held in Eversept’s Managed Accounts.

    ** Note: As of September 30, 2024, Eversept and its controlling persons were the beneficial owners of approximately 7.5% of the outstanding Shares, based on 27,598,871 shares of Common Stock of the Issuer outstanding as of October 25, 2024, as reported in the Issuer’s Form 10-Q filed on October 30, 2024, including 0.5% of the outstanding Shares held in Eversept’s Managed Accounts.

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5.  Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     ¨.

     

    Instruction. Dissolution of a group requires a response to this item.

     

       
     

     

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable. 

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.  Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.  Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.  Certification.

     

          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
             
         

    Exhibits

     

    Exhibit A - Joint Filing Agreement

     

     

       
     

     

    CUSIP No. 98888T107   13G   Page 8 of 9 Pages
             

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

      November 14, 2024
      Date
         
         
         
      EVERSEPT PARTNERS, L.P.
         
      By: /s/ Kamran Moghtaderi  
      Managing Principal
         
      EVERSEPT 1 LLC
         
      By: /s/ Kamran Moghtaderi  
      Managing Member
         
      KAMRAN MOGHTADERI
         
      /s/ Kamran Moghtaderi  

     

       
     

     

    Exhibit A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, each of the undersigned hereby constitutes and appoints Eversept Partners, L.P., a Delaware limited partnership, as its true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

        Date: November 14, 2024
       
    EVERSEPT PARTNERS, L.P.  
         
    By: /s/ Kamran Moghtaderi    
    Managing Principal  
         
         
    EVERSEPT 1 LLC  
         
    By: /s/ Kamran Moghtaderi    
    Managing Member  
         
    KAMRAN MOGHTADERI  
         
    /s/ Kamran Moghtaderi    

     

     

     

     

     

     

    Get the next $ZIMV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    3/18/2022Neutral
    Guggenheim
    More analyst ratings

    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ZimVie Inc.

      SC 13G - ZimVie Inc. (0001876588) (Subject)

      11/14/24 4:11:11 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

      SC 13G/A - ZimVie Inc. (0001876588) (Subject)

      11/14/24 10:58:06 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

      SC 13G/A - ZimVie Inc. (0001876588) (Subject)

      10/4/24 1:02:25 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    SEC Filings

    See more
    • SEC Form 10-Q filed by ZimVie Inc.

      10-Q - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:15:20 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:10:42 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by ZimVie Inc.

      DEFA14A - ZimVie Inc. (0001876588) (Filer)

      3/25/25 8:05:36 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Financials

    Live finance-specific insights

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025

      PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactu

      4/24/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results

      FY2024 Third Party Net Sales from Continuing Operations of $449.7 millionFY2024 Net Loss from Continuing Operations of $(33.8) million; Net Loss margin of (7.5%) FY2024 Adjusted EBITDA[1] from Continuing Operations of $60.0 million; Adjusted EBITDA[1] margin of 13.3%FY2024 GAAP diluted EPS from Continuing Operations of $(1.23) and adjusted diluted EPS[1] of $0.62 PALM BEACH GARDENS, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time. "2

      2/26/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on ZimVie with a new price target

      B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

      4/10/25 12:44:28 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie downgraded by Needham

      Needham downgraded ZimVie from Buy to Hold

      3/13/25 7:58:34 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie upgraded by Needham with a new price target

      Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00

      5/16/24 7:42:36 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025

      PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactu

      4/24/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Pioneers the Future of Molar Restoration with New Immediate Molar Dental Implant System

      PALM BEACH GARDENS, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its Immediate Molar Implant System in the United States. ZimVie is expanding its already clinically proven TSX® and T3 PRO® Implant systems with an immediate molar solution, simplifying challenging clinical scenarios for providers and shortening treatment times for patients requiring molar implants. Immediately replacing extracted molars with an implant can be difficult due to the complex multi-rooted anatomy and size of the tooth socket. ZimVie's Immediate Molar Implant System includes specially engineered instru

      4/21/25 8:00:00 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Officer Jamali Vafa converted options into 21,331 shares and covered exercise/tax liability with 9,333 shares, increasing direct ownership by 3% to 360,257 units (SEC Form 4)

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/3/25 4:03:34 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Kuntz Richard

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/2/25 5:22:27 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director King David P

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/2/25 4:47:15 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Leadership Updates

    Live Leadership Updates

    See more
    • ZimVie Announces Upcoming Changes to Company's Board of Directors

      PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

      3/13/25 4:15:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care